4,368 results match your criteria Cancer Science[Journal]


Reduction of intrapancreatic neural density in cancer tissue predicts poorer outcome in pancreatic ductal carcinoma.

Cancer Sci 2019 Feb 18. Epub 2019 Feb 18.

Gastric Surgery Division, National Cancer Center Hospital, Tokyo.

Neural invasion is one of the malignant features contributing to locally advanced and/or metastatic disease progression in patients with pancreatic ductal adenocarcinoma (PDAC). Few studies exist about the distribution and state of nerve fibers in PDAC tissue and about their clinicopathological impacts. The aim of this study was to investigate the clinicopathological characteristics and prognostic value of intrapancreatic neural alterations in patients with PDAC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13975DOI Listing
February 2019

Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 were associated with chemosensitivity for breast cancers.

Cancer Sci 2019 Feb 18. Epub 2019 Feb 18.

Department of Pathology, West China Hospital of Sichuan University, Chengdu, Sichuan Province, 610041, China.

The correlation of genetic alterations with responding to neoadjuvant chemotherapy (NAC) is not fully revealed. In this study, we enrolled 247 breast cancers receiving anthracycline-taxane-based NAC treatment. Next generation sequencing (NGS) panel containing 36 hot spot breast cancer related genes was used in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13976DOI Listing
February 2019

Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive NSCLC in Japan.

Cancer Sci 2019 Feb 18. Epub 2019 Feb 18.

Third Department of Internal Medicine, Division of Pulmonary Medicine & Medical Oncology, Wakayama Medical University, Wakayama, Japan.

We conducted a large-scale surveillance study as a post-marketing commitment to investigate safety and effectiveness of alectinib in patients with ALK-positive non-small-cell lung cancer (NSCLC) in Japan. Patients receiving 300mg twice-daily alectinib (September 2014 to June 2015) were monitored until termination of alectinib or completion of 18 months of treatment at 519 Japanese study sites. The primary endpoint was the incidence of adverse drug reactions (ADRs), which are important identified risks for alectinib in Japanese patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13977DOI Listing
February 2019

Enrichment of CLDN18-ARHGAP fusion gene in gastric cancers in young adults.

Cancer Sci 2019 Feb 16. Epub 2019 Feb 16.

Division of Screening for Molecular Target of Cancer, Graduate School of Medicine, Tohoku University, Sendai, Japan.

Gastric cancer in young adults has been pointed out to comprise a subgroup associated with distinctive clinicopathological features, including an equal gender distribution, advanced disease and diffuse-type histology. Comprehensive molecular analyses of gastric cancers have led to molecular-based classifications and to specific and effective treatment options available. The molecular traits of gastric cancers in young adults await investigations, which should provide a clue to explore therapeutic strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13967DOI Listing
February 2019

Identification of novel HLA-A*11:01-restricted CTL epitopes derived from the osteosarcoma antigen PBF.

Cancer Sci 2019 Feb 15. Epub 2019 Feb 15.

Department of Pathology, Sapporo Medical University School of Medicine, South-1, West-17, Chuo-ku, Sapporo, 060-8556, Japan.

Osteosarcoma is the most common malignancy of bone that affects young people. Neoadjuvant chemotherapy and surgery have significantly improved the prognosis. However, the prognosis of non-responders to chemotherapy is still poor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13973DOI Listing
February 2019

Rap1 signal modulators control the maintenance of hematopoietic progenitors in bone marrow and adult long-term hematopoiesis.

Cancer Sci 2019 Feb 15. Epub 2019 Feb 15.

Medical Innovation Center, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, 606-8507, Japan.

Adult long-term hematopoiesis depends on sustaining hematopoietic stem/progenitor cells (HSPCs) in bone marrow (BM) niches, where their balance of quiescence, self-renewal, and hematopoietic differentiation is tightly regulated. While various BM stroma cells that produce niche factors have been identified, regulation of the intrinsic responsiveness of HSPCs to the niche factors remains elusive. We previously reported that mice deficient for Sipa1, a Rap1 GTPase-activating protein, develop diverse hematopoietic disorders of late onset. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13974DOI Listing
February 2019

IFT20 promotes collective cancer cell invasion by regulating polarized organization of Golgi-associated microtubules.

Cancer Sci 2019 Feb 11. Epub 2019 Feb 11.

Division of Cell Physiology, Department of Physiology and Cell biology, Graduate School of Medicine, Kobe University, Kobe, 650-0017, Japan.

Collective invasion is an important strategy of cancers of epithelial origin, including colorectal cancer (CRC), to infiltrate efficiently into local tissues as collective cell groups. Within the groups, cells at the invasive front, called leader cells, are highly polarized and motile, thereby providing the migratory traction that guides the follower cells. However, its underlying mechanisms remain unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13970DOI Listing
February 2019

Clinical utility of circulating tumor DNA for colorectal cancer.

Cancer Sci 2019 Feb 11. Epub 2019 Feb 11.

Project for Development of Liquid Biopsy, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.

Colorectal cancer (CRC) is currently the most common types of cancer in Japan, and its prognosis has been improved because of development of diagnosis and advancement in treatments including surgery and chemotherapy. However, because of intra-tumor heterogeneity, and clonal evolution, tumors often develop resistance to treatments. Genotyping tumor tissue in search of somatic genetic alterations for actionable information has become routine examination in the clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13972DOI Listing
February 2019

Development of novel diagnostic system for pancreas cancer including early stages measuring mRNA of whole blood cells.

Cancer Sci 2019 Feb 11. Epub 2019 Feb 11.

Department of Gastroenterology, Kanazawa University Hospital.

Pancreatic ductal adenocarcinoma (PDAC) is the most life-threating disease among all digestive system malignancies. We developed a blood mRNA PDAC screening system using real-time detection PCR to detect the expression of 56 genes, to discriminate PDAC from non-cancer subjects. We performed a clinical study to assess the performance of the developed system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13971DOI Listing
February 2019
2 Reads

Comprehensive assay for the molecular profiling of cancer by target enrichment from formalin-fixed paraffin-embedded specimens.

Cancer Sci 2019 Feb 9. Epub 2019 Feb 9.

Division of Cellular Signaling, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

Tumor molecular profiling is becoming a standard of care for patients with cancer, but the optimal platform for cancer sequencing remains undetermined. We established a comprehensive assay, the Todai OncoPanel (TOP), which consists of DNA and RNA hybridization capture-based next-generation sequencing panels. A novel method for target enrichment, named the junction capture method, was developed for the RNA panel to accurately and cost-effectively detect 365 fusion genes as well as aberrantly spliced transcripts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13968DOI Listing
February 2019
1 Read

Development of microRNA-based therapeutic approaches for cancer patients.

Cancer Sci 2019 Feb 6. Epub 2019 Feb 6.

Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, 1-1, Tsukiji 5-chome, Chuo-ku, Tokyo, 104-0045, Japan.

Over the past few decades, small interfering RNAs (siRNAs) and microRNAs (miRNAs) have attracted a great deal of attention from researchers and clinicians. These molecules have been extensively studied from the standpoint of developing biopharmaceuticals against various diseases, including heart disease, diabetes, and cancers. siRNA suppresses only a single target, whereas each miRNA regulates the expression of the multiple target genes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13965DOI Listing
February 2019

Cationic amino acid transporter PQLC2 is a potential therapeutic target in gastric cancer.

Cancer Sci 2019 Feb 6. Epub 2019 Feb 6.

Biomedical Translational Research Center, KRIBB, 125 Gwahak-ro, Daejeon, Republic of Korea.

Tumor cells overexpress amino acid transporters to meet the increased demand for amino acids. PQ loop repeat-containing (PQLC)2 is a cationic amino acid transporter that may be involved in cancer progression. Here, we show that upregulation of PQLC2 is critical to gastric cancer (GC) development in vitro and in vivo. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/cas.13966
Publisher Site
http://dx.doi.org/10.1111/cas.13966DOI Listing
February 2019
2 Reads

Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models.

Cancer Sci 2019 Feb 6. Epub 2019 Feb 6.

Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.

Inhibition of the cyclin-dependent kinase (CDK) 4/6-retinoblastoma (RB) pathway is an effective therapeutic strategy against cancer. Here, we performed a preclinical investigation of the antitumor activity of SHR6390, a novel CDK4/6 inhibitor. SHR6390 exhibited potent antiproliferative activity against a wide range of human RB-positive tumor cells in vitro, and exclusively induced G arrest as well as cellular senescence, with a concomitant reduction in the levels of Ser780-phosphorylated RB protein. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13957DOI Listing
February 2019
2 Reads

IFN/STAT signaling controls tumorigenesis and the drug response in colorectal cancer.

Cancer Sci 2019 Feb 6. Epub 2019 Feb 6.

Department of Cell Biology, The Cancer Institute, Japanese Foundation for Cancer Research, Koto-Ku, Tokyo, 135-8550, Japan.

Colorectal cancer (CRC) is caused by genetic alterations, and comprehensive sequence analyses have revealed the mutation landscapes. In addition to somatic changes, genetic variations are considered important factors contributing to tumor development; however, our knowledge on this subject is limited. Familial adenomatous polyposis coli (FAP) is an autosomal-dominant inherited disease caused by germline mutations in the adenomatous polyposis coli (APC) gene. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/cas.13964
Publisher Site
http://dx.doi.org/10.1111/cas.13964DOI Listing
February 2019
7 Reads

Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors.

Cancer Sci 2019 Feb 6. Epub 2019 Feb 6.

National Cancer Center Hospital East, Kashiwa, Japan.

Capmatinib is a highly specific, potent, and selective MET inhibitor. This was an open-label, multicenter, dose-escalation, phase I study conducted in Japanese patients with advanced solid tumors (not selected based on their MET status). The primary objective was to determine the maximum tolerated dose (MTD) and/or highest studied dose being safe. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/cas.13956
Publisher Site
http://dx.doi.org/10.1111/cas.13956DOI Listing
February 2019
3 Reads

Female reproductive factors and risk of lymphoid neoplasm: The Japan Public Health Center-based Prospective Study.

Cancer Sci 2019 Feb 4. Epub 2019 Feb 4.

Epidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

Although a possible role of reproductive factors in lymphomagenesis has been hypothesized, results of epidemiological studies have been inconsistent. Here, we investigated the association between reproductive factors and risk of lymphoid neoplasm and its subgroups. We used data from a large-scale, population-based prospective study in a Japanese cohort with 42 691 eligible women aged 40-69 years from 1990-1994. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13962DOI Listing
February 2019
2 Reads

Sulfasalazine may modulate the CD44v9-xCT system and enhance CDDP-induced cytotoxic effects in metastatic bladder cancer.

Cancer Sci 2019 Feb 4. Epub 2019 Feb 4.

Department of Urology, Keio University School of Medicine, Tokyo, Japan.

The prognostic role of CD44v9, a variant isoform of CD44 and a new cell surface marker of cancer stem cells, remains unclear in bladder cancer (BC) patients. Furthermore, limited information is available on the functional role of sulfasalazine (SSZ), which may modulate the CD44v9-xCT system in order to enhance CDDP-induced cytotoxicity and inhibit the metastatic potential of BC. CD44v9 protein expression was examined immunohistochemically in 63 muscle invasive BC (MIBC) patients who underwent radical cystectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13960DOI Listing
February 2019

KLF2 inhibits hepatocarcinogenesis through negative regulation of the Hedgehog pathway.

Cancer Sci 2019 Feb 4. Epub 2019 Feb 4.

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong Province, 510120, P.R.China.

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. The most important reason for the occurrence of HCC is HCV or HBV infection. Moreover, genetic factors play an important role in the tumorigenesis of HCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13961DOI Listing
February 2019

Prothymosin-α Enhances PTEN Expression and Binds with TRIM21 to Regulate Keap1/Nrf2 Signaling in Human Bladder Cancer.

Cancer Sci 2019 Feb 4. Epub 2019 Feb 4.

Department of Urology, An-Nan Hospital, China Medical University, Tainan, Taiwan.

Prothymosin-α (PTMA) is a small, acidic protein that is usually transported into the nucleus and involves many cellular and immunologic functions. Previous studies demonstrated that aberrant location of PTMA expression exists in human bladder cancer, but the role of PTMA protein expression remains elusive. In this study, we created ectopic nuclear or cytoplasmic PTMA expression in human bladder cancer cells by infecting lentiviruses carrying wild-type, or deleted nuclear localization signal of PTMA gene. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13963DOI Listing
February 2019
1 Read

Correction.

Authors:

Cancer Sci 2019 Feb;110(2):833

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13926DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361577PMC
February 2019

Correction.

Authors:

Cancer Sci 2019 Feb;110(2):834-835

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13939DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361579PMC
February 2019

GATA2 hypomorphism induces chronic myelomonocytic leukemia in mice.

Cancer Sci 2019 Feb 2. Epub 2019 Feb 2.

Department of Molecular Hematology, Tohoku University Graduate School of Medicine, Sendai, Japan.

The transcription factor GATA2 regulates normal hematopoiesis, particularly in stem cell maintenance and myeloid differentiation. Various heteroallelic GATA2 gene mutations are associated with a variety of hematological neoplasms, including myelodysplastic syndromes and leukemias. Here, we report that impaired GATA2 expression induces myelodysplastic and myeloproliferative neoplasm development in elderly animals, and this neoplasm resembles chronic myelomonocytic leukemia in humans. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cas.13959
Publisher Site
http://dx.doi.org/10.1111/cas.13959DOI Listing
February 2019
12 Reads

PD-L1 disruption by CRISPR/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.

Cancer Sci 2019 Jan 31. Epub 2019 Jan 31.

Department of Obstetrics and Gynecology, Institute of Advanced Medicine, Wakayama Medical University, Wakayama, Japan.

Programmed cell death ligand 1 (PD-L1) on tumor cells suppresses anti-tumor immunity and has an unfavorable prognostic impact in ovarian cancer patients. We herein report the pathophysiological and therapeutic impacts of PD-L1 disruption in ovarian cancer. PD-L1 was genetically disrupted in the murine ovarian cancer cell line ID8 using clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-mediated genome editing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13958DOI Listing
January 2019
1 Read

Tumor necrosis factor receptor modulator spermatogenesis-associated protein 2 is a novel predictor of outcome in ovarian cancer.

Cancer Sci 2019 Jan 30. Epub 2019 Jan 30.

Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Innsbruck, Austria.

Inflammation plays a crucial role in the pathogenesis of cancer with tumor necrosis factor-α (TNF-α) as a key mediator. Recently, spermatogenesis-associated protein 2 (SPATA2) was identified as a TNF receptor modulator which is required for TNF-induced inflammation and apoptosis. The available data on TNF-α in ovarian cancer (OC) are inconsistent, and SPATA2 is completely uncharacterized in tumorigenesis. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cas.13955
Publisher Site
http://dx.doi.org/10.1111/cas.13955DOI Listing
January 2019
2 Reads

Epstein-Barr virus strain variation and cancer.

Cancer Sci 2019 Jan 30. Epub 2019 Jan 30.

Division of Microbiology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University.

Epstein-Barr virus (EBV) is a human tumor virus and is etiologically linked to various malignancies. Certain EBV-associated diseases, such as Burkitt lymphomas and nasopharyngeal carcinomas (NPCs), are endemic and exhibit biased geographical distribution worldwide. Recent advances in deep sequencing technology enabled high-throughput sequencing of the EBV genome from clinical samples. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cas.13954
Publisher Site
http://dx.doi.org/10.1111/cas.13954DOI Listing
January 2019
4 Reads

The long noncoding RNA LUCAT1 promotes CRC tumorigenesis by targeting RPL40-MDM2-p53 pathway through binding with UBA52.

Cancer Sci 2019 Jan 28. Epub 2019 Jan 28.

Department of Anatomy, Histology and Embryology, Nanjing Medical University, Nanjing, 211166, China.

Colorectal cancer (CRC) is the third most commonly diagnosed cancer in both men and women in the United States. However, the underlying molecular mechanisms that drive CRC tumorigenesis are still not clear. Several studies have demonstrated that long non-coding RNAs (lncRNAs) have important roles in tumor development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13951DOI Listing
January 2019
1 Read

The deubiquitinase USP9X regulates the stability and function of E3 ubiquitin ligase RNF115 in breast cancer cells.

Cancer Sci 2019 Jan 28. Epub 2019 Jan 28.

Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, 200032, China.

The E3 ubiquitin ligase ring finger protein 115 (RNF115) is overexpressed in over half of human breast tumors and is implicated in the pathogenesis and progression of breast cancer. However, the mechanism behind RNF115 overexpression in breast tumors remains largely unknown. Here we report that ubiquitin-specific protease 9X (USP9X), a substrate-specific deubiquitinating enzyme, stabilizes RNF115 and thereby regulates its biological functions in breast cancer cells. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cas.13953
Publisher Site
http://dx.doi.org/10.1111/cas.13953DOI Listing
January 2019
1 Read

Glucose starvation induces resistance to metformin through the elevation of mitochondrial multidrug resistance protein1.

Cancer Sci 2019 Jan 28. Epub 2019 Jan 28.

Laboratory of Veterinary Clinical Pathology, College of Veterinary Medicine, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, The Republic of Korea.

Metformin, a drug for type 2 diabetes mellitus, has shown therapeutic effects for various cancers. However, it had no beneficial effects on survival rate of human malignant mesothelioma (HMM) patients. This study was performed to elucidate the underlying mechanism of metformin resistance in HMM cells. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cas.13952
Publisher Site
http://dx.doi.org/10.1111/cas.13952DOI Listing
January 2019
3 Reads

LncRNA MIR22HG inhibits growth, migration and invasion through regulating miR-10a-5p/NCOR2 axis in hepatocellular carcinoma cells.

Cancer Sci 2019 Jan 25. Epub 2019 Jan 25.

Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 200032, China.

Despite the rapidly identified numbers of lncRNAs in human, the exploration on the molecular mechanisms of lncRNAs are largely lagged behind, because the molecular mechanisms of lncRNAs could be various and complex in different conditions. In this study, we found a new molecular mechanism for a versatile molecule, MIR22HG. MIR22HG is a lncRNA that contributes to the initiation and progression of many human cancers, including hepatocellular carcinoma (HCC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13950DOI Listing
January 2019
1 Read

Frizzled 2-induced EMT correlates with vasculogenic mimicry, stemness and Hippo signaling in hepatocellular carcinoma.

Cancer Sci 2019 Jan 24. Epub 2019 Jan 24.

Department of Hepatobiliary Surgery, Nanfang Hospital of Southern Medical University, Guangzhou, China.

Prior observation has indicated that Frizzled 2 (FZD2)-induced epithelial-mesenchymal transition (EMT) may be a key step in metastasis and early recurrence of hepatocellular carcinoma (HCC). However, the mechanism underlying tumor development and progression due to aberrant FZD2 expression is poorly defined. Here, we provide evidence that FZD2 is a driver for EMT, cancer stem cell (CSC) property, and vasculogenic mimicry (VM) in HCC. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cas.13949
Publisher Site
http://dx.doi.org/10.1111/cas.13949DOI Listing
January 2019
3 Reads

Maintenance of long remission in adult T-cell leukemia by Tax-targeted vaccine: a hope for disease-preventive therapy.

Cancer Sci 2019 Jan 22. Epub 2019 Jan 22.

Department of Hematology, National Kyushu Cancer Center, Fukuoka, Japan.

Adult T-cell leukemia/lymphoma (ATL) is an aggressive lymphoproliferative disease caused by human T-cell leukemia virus type-1 (HTLV-1). Multi-agent chemotherapy can reduce ATL cells but frequently allows relapses within a short period of time. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) following chemotherapy is now a standard therapy for ATL in Japan as it can achieve long-term remission in about one third of recipient ATL patients, however it also has a risk of treatment-related mortality. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cas.13948
Publisher Site
http://dx.doi.org/10.1111/cas.13948DOI Listing
January 2019
5 Reads

Pharmacologic Characterization of Fluzoparib, a Novel Poly(ADP-ribose) polymerase (PARP) Inhibitor Undergoing Clinical Trials.

Cancer Sci 2019 Jan 21. Epub 2019 Jan 21.

Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.

Poly(ADP-ribose) polymerase (PARP) enzymes play an important role in repairing DNA damage and maintaining genomic stability. Olaparib, the first-in-class PARP inhibitor, has shown remarkable clinical benefits in the treatment of BRCA-mutated ovarian or breast cancer. However, the undesirable hematological toxicity and pharmacokinetic properties of olaparib limit its clinical application. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cas.13947
Publisher Site
http://dx.doi.org/10.1111/cas.13947DOI Listing
January 2019
20 Reads

Nitric oxide inhibits autophagy and promotes apoptosis in hepatocellular carcinoma.

Cancer Sci 2019 Jan 18. Epub 2019 Jan 18.

Institution of Hepatology, First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an City, China.

Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related mortality worldwide. The expression of nitric oxide synthase (NOS) and the inhibition of autophagy have been linked to cancer cell death. However, the involvement of serum nitric oxide (NO), the expression of NOS and autophagy have not been investigated in HCC. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cas.13945
Publisher Site
http://dx.doi.org/10.1111/cas.13945DOI Listing
January 2019
13 Reads

Roles of EphA1/A2 and ephrin-A1 in cancer.

Cancer Sci 2019 Jan 18. Epub 2019 Jan 18.

Department of Pharmacology, Tokyo Women's Medical University, Shinjuku, Tokyo, Japan.

The biological functions of the Eph/ephrin system have been intensively investigated and well documented so far since its discovery in 1987. Although the Eph/ephrin system has been implicated in pathological settings such as Alzheimer's disease and cancer, the molecular mechanism of the Eph/ephrin system in those diseases is not well understood. Especially in cancer, recent studies have demonstrated that most of Eph and ephrin are up- or down-regulated in various types of cancer, and have been implicated in tumor progression, tumor malignancy, and prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13942DOI Listing
January 2019
1 Read

Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in murine pancreatic cancer models.

Cancer Sci 2019 Jan 18. Epub 2019 Jan 18.

Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy associated with an extremely poor prognosis. Chemotherapy, such as gemcitabine (GEM), is the only treatment for PDAC patients who are not suitable for radical surgical treatment; however, its anti-tumor efficacy is limited. In this study, we investigated the host immune system response in murine PDAC models undergoing GEM treatment. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cas.13944
Publisher Site
http://dx.doi.org/10.1111/cas.13944DOI Listing
January 2019
8 Reads

REV7 confers radioresistance of esophagus squamous cell carcinoma by recruiting PRDX2.

Cancer Sci 2019 Jan 18. Epub 2019 Jan 18.

State Key Lab of Radiation Medicine and Protection, Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, China.

Radiotherapy has been widely used for the clinical management of esophageal squamous cell carcinoma. However, radioresistance remains a serious concern that prevents the efficacy of esophageal squamous cell carcinoma (ESCC) radiotherapy. REV7, the structural subunit of eukaryotic DNA polymerase ζ, has multiple functions in bypassing DNA damage and modulating mitotic arrest in human cell lines. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cas.13946
Publisher Site
http://dx.doi.org/10.1111/cas.13946DOI Listing
January 2019
11 Reads

Phase II trial of aflibercept with FOLFIRI as a 2nd-line treatment for Japanese patients with metastatic colorectal cancer.

Cancer Sci 2019 Jan 18. Epub 2019 Jan 18.

Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Aflibercept targets vascular endothelial growth factor. This study involved assessing the efficacy, safety, and pharmacokinetics of aflibercept plus 5-fluorouracil/levofolinate/irinotecan (FOLFIRI) as a second-line treatment for metastatic colorectal cancer (mCRC) in Japanese patients. Aflibercept (4 mg/kg) plus FOLFIRI was administered every 2 weeks in 62 patients with mCRC until disease progression, unacceptable toxicity, or patient withdrawal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13943DOI Listing
January 2019
2 Reads

Inhibiting the MCM8-9 complex selectively sensitizes cancer cells to cisplatin and olaparib.

Cancer Sci 2019 Jan 16. Epub 2019 Jan 16.

Department of Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.

MCM8 and MCM9 are paralogues of the MCM2-7 eukaryotic DNA replication helicase proteins and play a crucial role in a homologous recombination-mediated repair process to resolve replication stress by fork stalling. Thus, deficiency of MCM8-9 sensitizes cells to replication stress caused, for example, by platinum compounds that induce interstrand cross-links. It is suggested that cancer cells undergo more replication stress than normal cells due to hyperstimulation of growth. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13941DOI Listing
January 2019
1 Read

Bazedoxifene exhibits growth suppressive activity by targeting interleukin-6/glycoprotein 130/signal transducer and activator of transcription 3 signaling in hepatocellular carcinoma.

Cancer Sci 2019 Jan 16. Epub 2019 Jan 16.

Division of Cardiology, Departments of Internal Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

The interleukin (IL)-6/glycoprotein (GP)130/signal transducer and activator of transcription (STAT)3 pathway is emerging as a target for the treatment of hepatocellular carcinoma. IL-6 binds to IL-6R, forming a binary complex, which further combines with GP130 to transduce extracellular signaling by activating STAT3. Therefore, blocking the interaction between IL-6 and GP130 may inhibit the IL-6/GP130/STAT3 signaling pathway and its biological effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13940DOI Listing
January 2019
3 Reads

Shortcuts to intestinal carcinogenesis by genetic engineering in organoids.

Cancer Sci 2019 Jan 13. Epub 2019 Jan 13.

Department of Molecular Carcinogenesis, Chiba Cancer Center Research Institute, Chiba, Japan.

Inactivation of the Adenomatous polyposis coli (APC) gene is an initiating and the most relevant event in most sporadic cases of colorectal cancer, providing a rationale for using Apc-mutant mice as the disease model. Whereas carcinogenesis has been observed only at the organism level, the recent development of the organoid culture technique has enabled long-term propagation of intestinal stem cells in a physiological setting, raising the possibility that organoids could serve as an alternative platform for modeling colon carcinogenesis. Indeed, it is demonstrated in the present study that lentivirus-based RNAi-mediated knockdown of Apc in intestinal organoids gave rise to subcutaneous tumors upon inoculation in immunodeficient mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13938DOI Listing
January 2019
1 Read

Differential regulation of CpG island-methylation within divergent and unidirectional promoters in colorectal cancer.

Cancer Sci 2019 Jan 13. Epub 2019 Jan 13.

Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.

The silencing of tumor suppressor genes by promoter CpG island (CGI) methylation is an important cause of oncogenesis. Silencing of MLH1 and BRCA1, two examples of oncogenic events, results from promoter CGI methylation. Interestingly, both MLH1 and BRCA1 have a divergent promoter, from which another gene on the opposite strand is also transcribed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13937DOI Listing
January 2019
1 Read

ZNF671 DNA methylation as a molecular predictor for the early recurrence of serous ovarian cancer.

Cancer Sci 2019 Jan 11. Epub 2019 Jan 11.

Division of Cancer Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Serous ovarian cancer is the most frequent type of epithelial ovarian cancer. Despite the use of surgery and platinum-based chemotherapy, many patients suffer from recurrence within 6 months, termed platinum resistance. Currently, the lack of relevant molecular biomarkers for the prediction of the early recurrence of serous ovarian cancers is linked to the poor prognosis. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cas.13936
Publisher Site
http://dx.doi.org/10.1111/cas.13936DOI Listing
January 2019
2 Reads

UNC5D, suppressed by promoter hypermethylation, inhibits cell metastasis by activating DAPK1 in prostate cancer.

Cancer Sci 2019 Jan 11. Epub 2019 Jan 11.

Department of Laboratory, Tianjin Medical University Cancer Institute and Hospital, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin, 300060, PR China.

Prostate cancer (PCa) death primarily occurs due to metastasis of the cells, but little is known about the underlying molecular mechanisms. This study aimed to evaluate the expression of UNC5D, a newly identified tumor suppressor gene, analyze its epigenetic alterations, and elucidate its functional relevance to PCa metastasis. Meta-analysis of publicly available microarray datasets revealed that UNC5D expression was frequently down-regulated in PCa tissues and inversely associated with the PCa metastasis. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cas.13935
Publisher Site
http://dx.doi.org/10.1111/cas.13935DOI Listing
January 2019
5 Reads

Optimal therapeutic strategy using antigen-containing liposomes selectively delivered to antigen-presenting cells.

Cancer Sci 2019 Jan 10. Epub 2019 Jan 10.

Laboratory for Immunotherapy, RIKEN Center for Integrative Medical Science (IMS), Yokohama, Japan.

Recent immunotherapies have shown clinical success. In particular, vaccines based on particulate antigen (Ag) are expected to be implemented based on their efficacy. In the current study, we describe a strategy entailing Ag-encapsulating PEG-modified liposomes (PGL-Ag) as antigen protein delivery devices and show that the success of the liposome depends on the antigen-presenting cell (APC) capacity; after administration of PGL-Ag, dendritic cells (DCs) in particular take up the Ag and subsequently prime T cells. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cas.13934
Publisher Site
http://dx.doi.org/10.1111/cas.13934DOI Listing
January 2019
9 Reads

Soluble factors derived from neuroblastoma cell lines suppress dendritic cell differentiation and activation.

Cancer Sci 2019 Jan 10. Epub 2019 Jan 10.

Department of Medical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Dendritic cells (DC) play a key role in the initiation of both antitumor immunity and immunological tolerance. It has been demonstrated that exposure to soluble factors produced by tumor cells modulates DC functions and induces tolerogenic DC differentiation. In this study, we investigated the effects of neuroblastoma cell line-derived soluble factors on DC differentiation. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cas.13933
Publisher Site
http://dx.doi.org/10.1111/cas.13933DOI Listing
January 2019
7 Reads

KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer.

Cancer Sci 2019 Jan 7. Epub 2019 Jan 7.

Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan.

Pembrolizumab, a humanized monoclonal antibody against programmed death 1 (PD-1), has been shown to improve overall survival (OS) in patients with previously treated advanced non-small-cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) tumor proportion score (TPS) ≥1%. We report safety and efficacy results from the phase 1b KEYNOTE-025 study, which evaluated pembrolizumab in Japanese patients with previously treated NSCLC. Eligible patients had histologically/cytologically confirmed advanced NSCLC with PD-L1 TPS ≥1% and had received ≥1 platinum-doublet chemotherapy. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cas.13932
Publisher Site
http://dx.doi.org/10.1111/cas.13932DOI Listing
January 2019
11 Reads

p53/Lactate dehydrogenase A axis negatively regulates aerobic glycolysis and tumor progression in breast cancer expressing wild-type p53.

Cancer Sci 2019 Jan 7. Epub 2019 Jan 7.

The Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Changsha, China.

Tumor suppressor p53 is a master regulator of apoptosis and plays key roles in cell cycle checkpoints. p53 responds to metabolic changes and alters metabolism through several mechanisms in cancer. Lactate dehydrogenase A (LDHA), a key enzyme in glycolysis, is highly expressed in a variety of tumors and catalyzes pyruvate to lactate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13928DOI Listing
January 2019
1 Read

Preclinical pharmacodynamics evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma.

Cancer Sci 2019 Jan 7. Epub 2019 Jan 7.

Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, West China School of Pharmacy, Sichuan University, Chengdu, 610041, P. R. China.

Despite tremendous efforts, the clinical prognosis of pancreatic ductal adenocarcinoma (PDAC) remains disappointing. There is an urgent need to develop more effective treatment strategies to improve the prognosis of patients with PDAC. In this study, we evaluate the anti-PDAC effects of LY-1816, which is a new multi-kinase inhibitor developed by us. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cas.13929
Publisher Site
http://dx.doi.org/10.1111/cas.13929DOI Listing
January 2019
6 Reads